Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?

Nurse Pract. 2017 Dec 15;42 Suppl 12:3-9. doi: 10.1097/01.NPR.0000526627.04268.80.

Abstract

Cardiovascular (CV) risk remains in some patients who are treated with statins. Evidence supports a role for triglycerides (TGs) in CV disease. TG-lowering agent outcomes studies have been inconsistent, but eicosapentaenoic acid significantly reduced coronary events in hypercholesterolemic patients who were treated with statins. Ongoing outcomes studies will clarify the role of TG-lowering treatments in CV risk reduction.

MeSH terms

  • Cardiovascular Diseases
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypertriglyceridemia / drug therapy*
  • Triglycerides / blood

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Triglycerides